CCS
CYTK icon

Crosspoint Capital Strategies’s Cytokinetics CYTK Stock Holding History

Crosspoint Capital Strategies’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-443
Closed -$4K – 251
2015
Q4 		$4K Buy
+443
New +$4.34K ﹤0.01% 832

Other funds holding CYTK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Crosspoint Capital Strategies's CYTK Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Cytokinetics (CYTK) in Q1 2016, closing a stake of 443 shares — an estimated $4K sold.

Crosspoint Capital Strategies first reported a position in CYTK in Q4 2015 and held it in 1 quarter. The position peaked at $4K in Q4 2015. 109 funds tracked by Wall St. Rank hold CYTK as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining Cytokinetics position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 443 Cytokinetics shares in Q1 2016, an estimated $4K.
  • Crosspoint Capital Strategies first reported a position in Cytokinetics in Q4 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Cytokinetics position peaked at $4K in Q4 2015.
  • 109 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.